|
Technique for Creating Authentic Rat Embryonic Stem Cells
31 December 2008
The technique licensed exclusively by Stem Cell Sciences, is expected to allow the generation of rat ES cells to create genetically modified animals.
|
|
|
|
LifeCycle Pharma Moves LCP-Tacro™ into Clinical Phase 3
30 December 2008
LifeCycle enrolls the first patient in the clinical trial program for use of LCP-Tacro™ in the prevention of organ rejection in stable kidney transplant patients.
|
|
|
|
Cytokinetics Retains Development and Commercialization Rights to Ispinesib and SB-743921
29 December 2008
GSK will not exercise its option to license ispinesib or SB-743921 as provided under the collaboration agreement with Cytokinetics entered in 2001.
|
|
|
|
King Pharmaceuticals Initiates Phase II Clinical Trial Evaluating T-62 as a Treatment for Neuropathic Pain
29 December 2008
The Phase II clinical trial is a double-blind, placebo-controlled study assessing the analgesic efficacy and safety of T-62 in subjects with postherpetic neuralgia.
|
|
|
|
Supernus Initiates Phase III Clinical Trial for Epliga™ in Refractory Partial Onset Epileptic Seizures
29 December 2008
Once-per-day therapy is designed to improve patient compliance and reduce adverse events as compared with reference product Trileptal®.
|
|
|
|
Alnylam Advances RNAi Therapeutics Pipeline and Files Company’s First Systemic Delivery IND
26 December 2008
The Company has filed an IND for ALN-VSP, an RNAi therapeutic for the treatment of liver cancers.
|
|
|
|
Cellumen Expands Discovery Toxicology Services with Cardiac Hypertrophy Panel
26 December 2008
Cellumen announce a new Cellular Systems Biology panel to predict cardiac hypertrophy earlier in the drug discovery and development process.
|
|
|
|
ImmunoCellular Therapeutics’ Cancer Vaccine Demonstrates Immune Response against Brain Cancer in Clinical Trial
26 December 2008
Company presents promising clinical data from a Phase I trial evaluating dendritic cell-based cancer vaccine for the treatment of glioblastoma.
|
|
|
|
Provectus Pharmaceuticals Adds Seventh Center to Phase 2 Clinical Trial of PV-10
26 December 2008
The expansion of Phase 2 trial for metastatic melanoma continues to University of Louisville.
|
|
|
|
Common Treatment for Chronic Prostatitis Fails to Reduce Symptoms
23 December 2008
According to a clinical trial sponsored by the NIDDK, Alfuzosin failed to significantly reduce symptoms in recently diagnosed men having chronic prostatitis.
|
|
|
|
National Cancer Institute Awards SBIR Contract to Rules-Based Medicine
23 December 2008
RBM to expand research collaboration with Correlogic Systems aimed at multiplex diagnostic tests for ovarian cancer.
|
|
|
|
Mouse Studies Show Gene Therapy Method Holds Promise in Targeting Tumor Blood Vessels for Destruction
22 December 2008
Researchers develop a method for delivering a therapeutic gene to the blood vessels of tumors in mice that damages the blood vessels and disrupts the blood flow to tumors.
|
|
|
|
Baxter Receives EMEA Positive Opinion for CELVAPAN, the First Cell Culture-Based Pandemic Flu Vaccine
19 December 2008
Clinical data from a Phase III and subsequent booster study demonstrate safety, immune response and cross-protective memory.
|
|
|
|
Pfizer and Celldex Announce Amendment to ACT III Study of CDX-110 in Glioblastoma Multiforme
19 December 2008
The ACT III study will provide a multi-center non-randomized dataset for CDX-110 in patients with newly diagnosed GBM.
|
|
|
|
StemCells Inc. Receives FDA Approval to Initiate Clinical Trial of HuCNS-SC® Cells in a Myelin Disease
19 December 2008
The Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for Pelizaeus-Merzbacher Disease.
|
|
|
|
Sucampo Initiates Phase 1 Study of SPL-017 for Peripheral Arterial Disease
19 December 2008
The randomized, double-blind, placebo-controlled, single-center, single ascending dose study will evaluate the safety and pharmacokinetic profile of SPL-017.
|
|
|
|
VistaGen and WARF Sign License Agreement for Human Embryonic Stem Cell Technology
19 December 2008
The license is expected to accelerate Vistagen’s commercial programs focused on stem cell-based ‘clinical trials in a Test Tube™.
|
|
|
|
FDA Signs Contract with Entelos to Predict Cardiovascular Adverse Events
18 December 2008
FDA to use the Entelos® Cardiovascular PhysioLab® to assess the cardiovascular safety and efficacy of a specific drug class and a set of drugs within that class.
|
|
|
|
Mouse Studies Show Gene Therapy Method Holds Promise in Targeting Tumor Blood Vessels for Destruction
18 December 2008
Cancer researchers develop method for delivering a therapeutic gene specifically to the blood vessels of tumors in mice.
|
|
|
|
New Data Show Zometa® Enhances Impact of Chemotherapy on Reducing Breast Tumor Size
15 December 2008
Adding Zometa to chemotherapy prior to surgery led to an additional 33% reduction in tumor size, resulting in fewer mastectomies.
|
|
|
|
VIVUS Initiates Avanafil Phase 3 Trials in Males with ED
15 December 2008
The REVIVE study is a randomized, double-blind, placebo-controlled, efficacy and safety study of avanafil in men with a history of ED.
|
|
|
|
pSivida new Clinical Trial for Drug Delivery Device in AMD
12 December 2008
The Company begins clinical trial using its Medidur™ technology to assess the safety and efficacy of Iluvien in patients with bilateral geographic atrophy.
|
|
|
|
Human Genome Sciences Announces Albuferon® Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
11 December 2008
Albuferon met its primary endpoint of non-inferiority to Pegasys in the ACHIEVE 2/3 trial in patients with genotypes 2 and 3 chronic hepatitis C.
|
|
|
|
Phosphagenics Announce Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine
11 December 2008
The trial demonstrates increased dermal penetration of TPM/Lidocaine compared to topical anaesthetic Xylocaine®.
|
|
|
|
Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia
10 December 2008
The ongoing, open-label, dose escalation study shows durable clinical responses in patients treated with AC220.
|
|
|
|
BioWa Licenses POTELLIGENT® Technology to GSK for Use in Antibody Development and Commercialization
09 December 2008
GSK gains right to use the technology for developing and commercializing antibodies with enhancement of antibody-dependent cellular cytotoxicity.
|
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce Expansion of Worldwide Collaboration
09 December 2008
The companies have agreed to co-develop dapagliflozin in Japan with AstraZeneca having operational and cost responsibility for all development.
|
|
|
|
Halozyme Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
09 December 2008
Halozyme grants exclusive, global rights to Roche for use of Enhanze™ Technology with biologics directed against fourth target.
|
|
|